https://www.biospace.com/article/runway-extension-key-to-survival-as-biopharma-faces-hard-times-ahead/

Hard times are forcing biopharma companies to extend their runways as they try to eke out every cent of value from their capital. This goes beyond conserving cash and prioritizing programs, affecting how they consider their opportunities.

The approach companies take depends upon their size. “At smaller companies, success depends on being able to generate positive data and thus attract investors,” Lance Minor, principal and life sciences national co-leader at BDO, told BioSpace. “If tightening the belt means focusing resources on getting to that next clinical readout, that’s an appropriate approach.”

In contrast, he continued, “With mid-sized companies, prioritizing their pipeline to meet earnings projections or better manage cash probably has a lower overall impact on the company and its stock price.”

Although some companies are delaying launches, “Extending the runway doesn’t necessarily mean slowing down,” Minor stressed. Instead, it may mean shepherding resources by narrowing clinical trials to focus on fewer indications rather than targeting multiple disease types simultaneously.

Analysts say financing options are likely to remain constrained for the remainder of this year.

The Neutrino Donut has joined BioNebraska and looks forward to connecting with our partners in the next few months.

Home

We will be at the Bio and Beers Happy Hour in September and look forward to meeting you there.

Bio & Beers Happy Hour

At this point, we are waiting for Congress to approve the advancement of the SBIR process. As expected, the politics is a major aspect of the stall and possible limitation of the approval process.

The larger change, a movement toward local support services, rather than nationwide contractors, is major shift in the management of SBIR processes.

In order to be successful, SBIR consulting partners will need to develop local relationships with key players and startups. This will involve more time spent understanding specific challenges by different group and creating the relationships with local and national partners.

The extent of your network will determine the future of your consulting services. The network is not only your clients, but also the contacts you can bring to a relationship.

The Neutrino Donut prides ourselves with our ability to create relationships with our clients and customize our services based on the needs of our clients. The flexibility to offer services or provide local partners to consulting engagements is key to this process.

The Neutrino Donut prides ourselves on the extent of our ability to provide corporate introductions for our clients in a variety of industries and contact points. Our network is massive and these relationships are key. We manage these contacts by providing targeted technology introductions and ensure the focus is on the technologies and startups of interest.

The SBIR world is changing. But, sales has always been about relationships. And coffee’s for closers only.

We close deals for our clients.

The Neutrino Donut, LLC has joined Life Sciences PA. Life Sciences Pennsylvania’s mission is to ensure Pennsylvania is the United States hub for the life sciences by creating a business and public policy environment which fosters life sciences growth and success.

The Donut will be attending their October event, Life Sciences Future, BioPharm. We will also be in Pittsburgh for their BioSciences breakfast.

The Neutrino Donut is expanding our reach of customers and partners as part of an aggressive growth strategy to manage changes in the SBIR processes.

https://us02web.zoom.us/webinar/register/WN_-ihVOzqERgWVkFzKEt6JRw

For many investigators, particularly those in biomedical research and technology, funding opportunities at the Department of Defense are a bit of a “black box”–less well understood and shrouded in myths such as “only for warfare equipment” or “must benefit those in Service”. The truth is that a large number of funding opportunities are available from the DoD that cover a surprisingly wide range of research areas and are available for myriad investigators, from entrepreneurs and junior investigators to established investigators and foundation directors. In this talk, we will shine some light on available funding from the DoD. Leveraging our years of experience navigating several of these opportunities, we aim to help individuals and institutions identify relevant DoD funding mechanisms and share some wisdom gleaned on how to succeed in winning their agreements and contracts. Webinar is provided in partnership with University of Kentucky Office of Technology Commercialization.

Speakers

Earle Hager

Managing Partner @Neutrino Donut

Mr. Hager is the Managing Partner of The Neutrino Donut (Direct Observation of the Neutrino Tau), a consultancy focused on the management and commercialization of science. He has managed strategic planning for company growth, customer management, and business development aspects. His specific target areas include biotech, healthcare, consumer goods, chemistry, IT, materials science, environmental, product innovation, strategic planning, and development of business development strategies. Mr. Hager has worked with corporate R&D groups introducing products, completed over 300 technology assessments and over 200 business development projects in innovative technologies, and also been part of many SBIR commercialization projects, writing multiple commercialization sections and consulting on many more. Projects include grant reviews for DoE, DoD, NIH, NSF, as well as US and foreign universities, SBIR grant development, and running multiple startups.

Speakers

Emilie Clemmens

@Artemis Editing

DoD Biomedical Funding Opportunities

and How to Get Them

Webinar Opportunity

For many investigators, particularly those in biomedical research and technology, funding opportunities at the Department of Defense are a bit of a “black box”–less well understood and shrouded in myths such as “only for warfare equipment” or “must benefit those in Service”. The truth is that a large number of funding opportunities are available from the DoD that cover a surprisingly wide range of research areas and are available for myriad investigators, from entrepreneurs and junior investigators to established investigators and foundation directors. In this talk, we will shine some light on available funding from the DoD. Leveraging our years of experience navigating several of these opportunities, we aim to help individuals and institutions identify relevant DoD funding mechanisms and share some wisdom gleaned on how to succeed in winning their agreements and contracts.

Webinar is provided in partnership with University of Kentucky Office of Technology Commercialization.

September 1, 2022 – 12:00pm EDT

Register for Webinar

https://us02web.zoom.us/webinar/register/WN_-ihVOzqERgWVkFzKEt6JRw

The Donut is reviewing several commercialization plans for NIH technologies. This includes medical devices and software systems. The review encompasses the evaluation of the technology and the market entry strategy.

The Neutrino Donut will be working with a startup on the development of their commercialization report. This will include all stages of writing and editing. The Donut conducts these engagements on a fixed price basis, to encourage higher levels of cooperation in the development of the report.

We asked physicists to predict the discoveries that will blow our minds in the coming years.

https://gizmodo.com/future-of-particle-physics-higgs-boson-10-year-annivers-1849134503

Since we are The Neutrino Donut, LLC and the Direct Observation of the NeUtrino Tau is part of the Standard Model, we would like to share this update.

From the link:

On July 4, 2012, scientists at CERN confirmed the observation of the Higgs boson, an elementary particle first proposed in the 1960s. The boson’s discovery was a momentous occasion, as it meant physicists were a step closer to probing the field associated with the boson, which gives particles mass.

But since 2012, particle physics hasn’t had another seismic event. Important discoveries have been made—measurements were taken of the muon’s behavior in a magnetic field, the W boson’s mass was more precisely measured, and new particles have been discovered—but nothing as jaw-dropping as the Higgs confirmation.

We work extensively with companies in the startup space. We assist them in the development of the commercialization strategy and identify customers and partners. We have worked extensively with companies in the medical device, energy, materials science, cybersecurity, and many other areas. The commercialization process is extensive, but cuts across all technologies.

We also work with international based companies who are considering the US markets or, in the case of university technologies, considering commercialization options with their US counterparts.  We understand how to assist these groups with the various processes for collaboration and market entry.

Market entry strategies, business development projects, technology assessments of commercial products are other examples. I have worked on projects in Hungary, Mexico, Chile, Korea, India, Ukraine, and many other countries.

There are funding opportunities for my company on the back end of this initial consulting. To be effective, I am willing to work with your organization on the risk of finding the companies who are seeking to move forward.